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Anion-Channel Blockade With Alinidine: A Specific 
Bradycardic Drug for Coronary Heart Disease 
Without Negative lnotropic Activity? 
BRIAN E. JASKI, MD, and PATRICK W. SERRUYS, MD 
In 14 patients undergoing cardiac catheterization 
for suspected coronary artery disease, alinidine, 0.6 
mg/kg, was administered intravenously to determine 
its effects on left ventricular (LV) function, coronary 
blood flow and myocardial oxygen consumption. To 
assess effects independent of changes in heart rate 
(HR), measurements were made at spontaneous 
and matched pacing HRs. At spontaneous HR, ali- 
nidlne decreased HR from 70 f 2 to 61 f 3 beats/ 
min (p <10v6). Peak rate of LV pressure decreased 
from 1,652 f 92 to 1,371 f 60 mm Hg/s (p <IO-r) 
and Vmax decreased from 47 f 3 to 41 f 2 s-l (p 
<10m4). Coronary sinus blood flow decreased from 
109 f 9 to 69 f 7 ml/min (p <O.Ol ) and myocardial 
oxygen consumption from 10.9 f 1.0 to 9.0 f 0.6 
ml Op/min (p <0.05). At a matched pacing HR of 96 
f 3 beats/min before and after alinidine adminis- 
tration, peak rate of LV pressure decreased from 
1,964 f 124 to 1,793 f 106 mm Hg/s (p <10v4) 
and Vmax from 60 f 5 to 56 f 4 s-l (p <0.02). 
Coronary sinus blood flow and myocardial oxygen 
consumption were not significantly changed at 
matched pacing HRs. The time constant of the first 
40 ms of LV isovolumic relaxation was prolonged by 
alinidine only during spontaneous HR. Thus, alinidine 
results in a bradycardia-dependent decrease in 
myocardial oxygen consumption. It has negative 
inotroplc properties independent of changes in HR 
and so is not a pure bradycardia-specific agent. 
(Am J Cardiol 1965;56:270-275) 
Alinidine is a new bradycardic agent that acts without 
&receptor blockade. ly2 As such, use of alinidine could 
avoid limitations associated with potentially undesir- 
able properties of ,&receptor blockade.3 Although its 
chemical structure is similar to that of clonidine, its 
pharmacologic spectrum of action is distinctly different 
with minimal, if any, vasodilating activity.l Millar and 
Vaughan Williams proposed that its bradycardic action 
may be mediated by a unique mechanism of anion-se- 
lective membrane channel blockade.4*5 In in vitro 
models, alinidine has slowed the rate of sinus node 
discharge,lp4 an in animals, decreased resting myocardial 
oxygen consumption (MVOz).@ In patients with cor- 
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onary artery disease limited by angina, alinidine de- 
creases heart rate (HR) at rest, prolongs the duration 
of exercise and increases the level of maximal work 
without symptoms.7Ts 
Even if alinidine acts through a new mechanism of 
anion-channel blockade, then it still must be deter- 
mined whether the drug acts as a unique specific bra- 
dycardic agent. Controversy exists over whether alini- 
dine, in humans, has negative inotropic properties as 
well.gJO Because changes in HR alone may alter global 
left ventricular (LV) function and metabolism, the di- 
rect effects of alinidine on the heart, other than 
bradycardia, are uncertain. 
Therefore, we assessed the acute hemodynamic and 
myocardial effects of an intravenous dose of alinidine 
in 14 patients undergoing routine catheterization for 
evaluation of suspected coronary artery disease. Indexes 
of LV function, MVOs and coronary blood flow were 
measured before and after administration of the drug. 
To assess the effects of alinidine independent of changes 
in HR, measurements were also made at multiple 
matched atria1 paced HRs. 
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Methods 
Study population (Table I): The mean age of the patients 
was 54 i 3 years and mean angiographic ejection fraction was 
55 f 4%. Two patients with atypical chest pain had normal 
“-_--~. c5ro?=2.:p .~;t;:&. “,,:,=‘&&& 2nd va&iiailng drugs were 
discontinued at least 24 hours before study, Patients were 
studied after an overnight fast without premeditation pre- 
ceding routine diagnostic angiography. 
Data collection: Catheterization was performed through 
a right brachial or right femoral approach. In 13 patients, a 
No. 8Fr double micromanometer-tipped catheter (Millar 
Instruments) was advanced into the left ventricle. In 1 patient, 
an 8Fr pigtail micromanometer-tipped catheter (Millar In- 
struments) was advanced into the left ventricle and briefly 
pulled back to the central aortic position during coronary 
blood flow measurements and then reintroduced. LV pressure 
was analyzed using a previously described on-line system to 
measure the following variables? HR, LV peak systolic 
pressure, end-diastolic pressure, peak positive and negative 
rates of LV pressure change (+dP/dt and -dP/dt), velocity 
of the contractile element (dP/dt/P) at a total pressure of 40 
mm Hg (Vce.&, peak measured velocity of the contractile 
element (peak Vce), Vce linearly extrapolated to 0 mm Hg 
(Vmax), and Tr and Ta, the 2. respective time constants for the 
early first 40 ms and late subsequent phases of LV isovolumic’ 
relaxation after the occurrence of peak -dP/dt.12 Mean aortic 
pressure (MAP) was determined by digital integration. The 
systolic pressure-rate product was calculated as HR X LVsys 
(beats/minmm Hg). 
A coronary sinus thermodilution catheter (Webster) was 
placed in the coronary sinus for measurement of coronary 
blood flow, withdrawal of coronary venous samples and atrial 
pacing. Coronary sinus flow (CSF) was determined by the 
thermodilution method of Ganz.13 Coronary vascular resis- 
tance (R) was calculated as MAP/CSF. Aortic arterial (Ao) 
and coronary.sinus (CS) oxygen saturation were measured by 
oximetry. MV0s was calculated as CSF X (Ao - CS) X he- 
moglobin concentration (in g/dl) X 0.0136. Alinidine serum 
concentration was measured by radioimmunoassay by the 
method of Arndts and Stahle.14 
Protocol: After placement of catheters, stable repeated LV 
pressures were measured and control coronary blood flow, 
oxygen saturations, and aortic pressure measurements were 
made. Control LV pressure measurements were then obtained 
at spontaneous HR followed by increasing atria1 paced HRs 
with increments of 5 to 10 beats/min between measurements. 
A maximal HR approximately 30 beats/min greater than the 
heart rate at rest was chosen to provide a range of HRs and 
minimize the likelihood of angina pectoris or atrioventricular 
block. At the maximal paced HR, coronary blood flow, oxygen 
saturations, and aostic pressures were determined. Pacing was 
discontinued and repeat control measurements made at a 
spontaneous HR. Alinidine, 0.6 mglkg, was then administered 
by a slow intravenous infusion over 3 minutes. LV measure- 
ments were made every 30 seconds for 4 minutes, coronary 
blood flow, oxygen saturations, and aortic pressures were 
determined, and a final set of spontaneous HR-LV measure- 
ments were made. An arterial sample was withdrawn to 
measure alinidine serum concentration. Patients were again 
atria1 paced at increasing HRs with increments of 5 to 10 
beats/min with measurements made at each HR up to an 
identical maximal paced HR as during the pacing measure- 
ments before alinidine. At this rate, coronary blood 
flow, oxygen saturations and aortic pressure were finally 
determined. 
analysis: Pressure measurements suitable for analysis were 
recorded in 13 patients. In each patient, comparisons before 
TABLE I Patient Characteristic Data 
Age W No. of Vessels 
Pt & Sex EF with >50% Stenoses 
1 27M I 3 
2 ,-^ . 4 i I=“< ii.34 1 
3 40% 0.60 1 
rz 
70F 
47M 0.69 0’ 
6 54M 0.56 1 
7 69M 0.36 
9” 49M 51F 0.65 4
: 
:: 73F 48M 0.16 47 i 
12 57M 0.66 f 
:i 69F 0M 0.59 64 : 
l No EF available because of ventricular ectopic activity during left 
ventriculoangiogram. 
EF = ejection fraction. 
and after the administration of alinidine were made at the 
spontaneous HR and at the minimal (low matched pacing, PI> 
and maximum (high matched pacing, P2) identical paced rates 
obtained before and after the drug. Coronary blood flow and 
WOe could be measured in 12 patients and were compared 
at spontaneous HR and matched maximal paced rate. 
Statistics: Results are expressed as the mean ?t standard 
error of the mean. Group data before and after alinidine ad- 
ministration were compared by a paired Student t test. A p 
value <0.05 was considered statistically significant. 
Results 
Spontaneous heart rate (Tables PI III): 
mean of 9.3 f 0.4 minutes after adminis ion, H 
decreased from 70 f 2 to 61 f 3 beats/min (-12.9%, p 
<10e6). LV systolic pressure decreased from 146 f 5 to 
140 f 6 mm Hg (4.1%, p cO.05) and LV end-diastolic 
pressure increased slightly, from 17.8 f 2.2 to 19.2 f 2.4 
mm Hg (7.9%, p qO.05). The rate-pressure product de- 
creased from 10.2 f 0.4 to 8.6 f 0.6 X lo3 beats/min.mm 
Hg (-15.7%, p <10-5). 
LV peak + dP/dt fell from 1,652 f 92 to 1,371 f 80 
mm Hg/s (17.0%, p <10M5). Vceao decreased 15.6%, peak 
Vce decreased 17.1%, and Vmax decreased 12.8%; all 
of these changes were statistically significant corn.- 
pared with control. LV peak -dP/dt decreased from 
1,950 f 96 to 1,845 f 106 mm Hg/s (6.1%, p cO.01). 
The time constants of isovolumic relaxation, Tr and 
Ts, increased 12.2% (p <O.OOl) and 10.5% (p <O.Ol), 
respectively. 
During CS flow measurements, CS flow fell from 109 
f 9 to 89 f 7 ml/min (-l&3%, p <O.O2). NIV02 de- 
creased significantly, from 10.9 f 1.0 to 9.0 f 0.8 ml 
OJmin (17.4%, p <0.05). 
Mean alinidine serum concentration determined 
preceding the final atria1 pacing in 12 patients was 790 
f 112 rig/ml. 
Matched atrial pacing (Tables I 
matched pacing rate (PI): At a matched pacing rate of 
74 $: 3 beats/min before and after alinidine adminis- 
tration, LV +dP/dt decreased from 1,681 f 89 to 1,479 
f 76 mm Hg/s (12.0%, p <10e5). LV -dP/dt decreased 
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TABLE II Left Ventricular Function During Control and After Alinidine Administration 
Control Alinidine A% p Value 
HR (beatslmin) 
LVsys (mm Hg) 
LVEDP (mm Hg) 
HR X LVsvs 
LV +dP/dt 
(mm Hg/s) 
Vce4s (s-l) 
Peak Vce (s-l) 
Vmax (s-l) 
LV -dP/dt (mm Hg/s) 
Ti (ms) 
T2 (ms) 
PSI 
P2 
PSI 
P2 
PSI 
P2 
S 
Pl 
P2 
S 
Pl 
P2 
S 
Pl 
P2 
psi 
P2 
psi 
P2 
psi 
P2 
S 
;: 
psi 
P2 
70 f 2 
74 f 3 
98 f 3 
148f5 
147 f 5 
143f6 
18f 2 
15 f 2 
lOf2 
10 f 0.4 
11 f 0.5 
14 f 0.6 
1,652 f 92 
1,681 f 89 
1,984 f 124 
32 f 2 
33 f 2 
41 f3 
35 f 3 
38 f 3 
52 f 5 
47 f 3 
1::: 
1,965 f 96 
2,017 f 103 
2,T47 f 123 
49 f 5 
48 f 5 
44 f 5 
38 f 3 
37 f 4 
31 f4 
61 f3 
74 f 3 
98 f 3 
140f6 
141 f 5 
138f 5 
lQf2 
16f 2 
11 f2 
9 f 0.6 
10 f 0.6 
14 f 0.6 
1,371 f 80 
1,479 f 76 
1,793 f, 106 
27 f 2 
29 f 2 
38 f 3 
29 f 2 
29 f 2 
48 f 5 
41 f 2 
44 f 3 
56 f 4 
1,845 f 106 
1,897 f 116 
2,098 f 121 
55 f 5 
51 f5 
44 f 5 
42 f 4 
37 f 3 
33 f 4 
-12.9 
0 
0 
-4.1 
-4.1 
2,” 
+2.6 
+6.9 
-3.: 
-315 
-17 
-12 
-9.6 
-15.6 
-12.1 
-7.3 
-17.1 
-10.5 
-7.7 
-12.8 
-10.2 
-6.7 
-6.1 
-5.9 
-2.3 
+12.2 
+6.2 
+18.5 
+8.5 
<10-s 
NS 
<o.oF 
<0.02 
<0.077 = NS 
<0.05 
NS 
NS 
<10-s 
<0.005 
NS 
:;;I; 
<O.OOl 
<10-s 
<10-d 
<0.005 
<O.OOl 
<O.OOl 
<0.02 
<10-b 
<O.OOl 
<0.02 
2% 
’ NS 
<O.OOl 
<0.05 
<o.oY 
% 
Values are mean f standard error of the mean (n = 13). 
HR = heart rate; HR X LV sys = rate-pressure product; LVsys = left ventricular systolic pressure: LVEDP 
= left ventricular end-diastolkc pressure; LV +dP/dt = peak positive first derivative of LV pressure; LV 
-dP/dt = peak negative dP/dt; NS = not significant; PI = low matched pacing; Ps = high matched pacing; 
Peak Vce = peak measured Vce; S = spontaneous; T,,Ts = time constants from biexponential fitting 
of the LV isovolumic pressure decay; Vcedo = velocity of the contractile element at 40 mm Hg total 
pressure; Vmax = Vce extrapolated to P = 0. 
from 2,017 f 103 to 1,897 f 116 mm Hgls (5.9%, p 
<0.02). Vcedc decreased 12.1% (p <10v4), peak Vce 
10.5% (p <O.OOl) and Vmax 10.2% (p <O.OOl). Tr de- 
creased slightly (6.2%, p <0.05) and Ts did not 
change. 
High matched pacing rate (E’s): At a matched pacing 
rate of 98 f 3 beats/min before and after alinidine ad- 
ministration, LV +dP/dt decreased from 1,984 f 124 
mm to 1,793 f 106 mm Hg/s (9.6%, p <O.OOl). Vcedc 
decreased 7.3% (p <0.005), peak Vce 7.7% (p <0.02), and 
Vmax 6.7% (p <0.02). There were no significant changes 
in either LV - dP/dt or T1 and Ts. Coronary flow and 
MVOs did not change during matched pacing (Fig. 1, 
2 and 3). 
Discussion 
These findings show that alinidine acts both as a 
negative chronotropic and negative inotropic agent in 
patients with coronary artery disease. After alinidine 
administration, spontaneous HR consistently de- 
creased, accompanied by decreases in indexes of con- 
tractility, coronary blood flow, and MV02. When pa- 
tients were paced at both low and high matched HRs, 
the decrease in multiple indexes of contractility per- 
sisted. MVOs measured at the higher pacing rate, 
however, no longer differed significantly from matched 
pacing control. Coronary vascular resistance was un- 
changed during spontaneous or paced HRs. 
Kobinger et all first reported in 1979 that in animal 
models, alinidine acts as a “specific” bradycardic agent 
in that its negative chronotropic effect appeared more 
prominent than its other cardiovascular effects. Millar 
and Vaughan Williams4 showed that alinidine decreased 
the spontaneous beating rate in isolated rabbit atria. By 
comparison, in this model, clonidine led to either no 
change or a slight increase in rate.15 This bradycardic 
action was not related to cholinergic, adrenergic, calci- 
um channel or fast inward current activity.4!5 Alter- 
ations in alinidine’s effects by replacement of extra- 
cellular chloride with other anions and intracellular 
sinoatrial recordings showing a reduction in the slope 
of slow diastolic depolarization were consistent with a 
mechanism of anion-selective channel blockade. In man, 
Kasper et all6 showed that a 40-mg dose of alinidine led 
to a 23% increase in PP cycle length with no change in 
PA, AH or HV intervals or QRS duration. 
Brutsaert et ali7 identified an additional effect of 
alinidine in rat ventricular cardiac cells that theoreti- 
cally could account for a change in myocardial perfor- 
mance. In rat ventricular cardiac cells, alinidine delayed 
the release of calcium from the intracellular membra- 
nous system with only minor effects on the total amount 
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TABLE 111 Coronary Flow and Myocardial Oxygen Consumption During Control and After 
Alinidine Administration 
Control Alinidine A% p Value 
HR (beats/min) S 69 f 2 61 f3 
P2 97 f 3 97 f 3 
80 @=pn “g ce 
62 
~^- iso 5 s iW f S 
‘l6i3 109 i 3 
CBF (ml/min) S 109 f 9 89 f 7 
P2 122f9 llOf8 
cv~lj;g-Q :2 1.08 3 f 0.10 1.20 05 f 0.08 
Art-CS O2 S 99 f 3 101 f 3 (ml/liter) P2 7 0
MV02 (ml/min) S 11 f 1 9fl 
P2 llf 1 11 f 1 
Values are mean f standard error of the mean (n = 12). 
-11.6 <O.OOl 
0 
-7.4 <o:o~; 
-6.0 <0.02 
-18.3 co.02 
-9.8 
(NS) 
+11.1 +2 9 <“.oN78 NS 
i-l.8 +3.8 2 
-17.4 <0.05 
-6.7 NS 
’ 
Art-CSOp = arterial-coronary sinus difference in oxygen content; CBF = coronary.sinus blood flow; 
CVR = coronary vascular resistance; HR = heart rate; MAP = mean aortic pressure; MVOp = myocardial 
oxygen consumption; NS = not significant; P2 = high matched pacing; S = spontaneous. 
of calcium released or on calcium reuptake, a phenom- 
enon they named activation stabilization. This selective 
delay in the kinetics of myocardial calcium release could 
lead to a mechanical asynergy in myocardial function 
equivalent to the effective decrease in LV performance 
associated with a diffuse intraventricular conduction 
defect.18 With no effect on electrical recordings, it is 
possible that a heterogeneous prolongation in the in- 
tracellular onset of mechanical activation could lead to 
a global change in the synergy of LV contraction and, 
thus, effectively reduce inotropic state. 
In patients with coronary artery disease and impaired 
LV function, Lijllgen et al9 observed a 16% decrease in 
HR at rest after a 20-mg intravenous dose of alinidine. 
Cardiac output remained unchanged as pulmonary 
FIGURE 1. Individual and group mean 
changes in heart rate (HR) and peak 
positive left ventricular dP/dt (LV -t- 
dP/dt) at spontaneous, low matched 
pacing, and high matched pacing heart 
rates after alinidine (Al) administra- 
tion. LV + dP/dt was significantly lower 
after alinidine at all heart rates. C = 
control. 
SPONTANEOUS 
Heart 
Rate 100 
(bpm) 
wedge pressure decreased 19%. Systolic pressure de- 
creased 7 to 8% and systemic vascular resistance did not 
change. With exercise, alinidine, compared with control, 
led to increases in stroke volume and cardiac output and 
a 28% decrease in pulmonary wedge pressure. Liillgen 
et al concluded that alinidine had no significant negative 
inotropic effects and improved cardiac performance 
during exercise. 
Most of our patients did not. have significant LV 
dysfunction, so it is difficult to compare our results to 
these data. In addition, we did not measure cardiac 
output to allow computation of stroke volume. 
In patients with unstable angina or myocardial in- 
farction, Simoons and HugenholtzlO found that with 
intravenous doses of up to 40 mg, alinidine led to a 13% 
C Al 
LV+dP/dt *"' 
(rnnHs/s) 
2000 
800 -I c 
LOW MATCHED HIGH MATCHED 
PACING 
120 120 
100 100 
80 80 
i 
60 60 
PACING 
2800 -j 2800 1 
2400 2400 
2000 2000 I 
1600 
I 
1600 
1200 1200 
800 4 c Al 800 -i c Al 
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dP/dt %0X 
2000 70 
mOHU-3 
;;jg ;G/f?zf 
1200 _I 30, 
c 
60 70 80 90 100 60 70 RO 90 100 
HEART RAE, bm! HEART RAIL bm 
FIGURE 2. Effects of alinidine on indexes of systolic function. Despite 
matched pacing heart rates, both peak positive left ventricular dP/dt 
(LV + dP/dt) and Vmax remained significantly lower after alinidine 
administration. 
decrease in HR. Although mean stroke volume and LV 
filling pressure did not change, in 3 patients drug- 
associated signs of heart failure developed, for which 
the drug was discontinued. 
In our study, spontaneous HR decreased 12.9% after 
a 0.6-mg/kg intravenous dose of alinidine, a decrease 
similar to that reported by other studies. This reduction 
in HR was accompanied by a 15.7% decrease in the 
rate-pressure product and 17.4% decrease in MVOs. 
At matched paced HRs, in almost all patients, mul- 
tiple indexes of contractility were reduced. The 12.1 and 
9.6% decrease in peak +dP/dt observed at low and high 
matched pacing rates, respectively, is similar to that 
after intravenous administration of 6.15 mg/kg of pro- 
pranolol in patients with coronary artery disease at a 
constant atria1 paced HR. r9 These changes occurred 
with no change in LV end-diastolic pressure. At the low 
matched rate, peak LV systolic pressure and mean 
aortic pressure were slightly lower. At the high matched 
rate, peak LV systolic pressure was unchanged and 
mean aortic pressure was slightly lower. Peak +dP/dt 
is insensitive to changes in afterload and should not 
be significantly affected by these minimal decreases in 
pressure. The uniform decrease in “load-independent” 
indexes of systolic function also supports the conclusion 
that the change in systolic function occurred indepen- 
dent of changes in loading. 
At spontaneous HR, alinidine decreased the peak rate 
of LV pressure decline (-dP/dt) and prolonged the time 
constants of both early and late isovolumic relaxation. 
These results would be anticipated from a’ reduction in 
HR or inotropic state. When compared at matched HRs, 
however, there were no differences in these indexes of 
relaxation with alinidine. This possible dissociation 
between the effect on LV contractility and relaxation 
would be unlike that observed with other negative in- 
otropic agents such as calcium channel blockers,21 and 
could be consistent with the drug’s alternative mode of 
action. 
That the decrease in contractility at matched pacing 
HRs was not associated with a significant decrease in 
MVOz is not surprising. Beta blockers also lead to no 
change in MVOz at matched paced HRs.22p23 This 
finding is consistent with the hypothesis that the an- 
ticipated decrease in MVOs after a decrease in inotropic 
state may be offset by an increase in ventricular diam- 
eter and systolic wall tension.24 
Why Lollgen et al9 failed to observe a negative ino- 
tropic effect with alinidine in patients with coronary 
artery disease and LV dysfunction is uncertain. The 
methods used in their study (right-sided cardiac cath- 
eterization) are much less sensitive than those used in 
HR LVSYS LVEDP HR+LVsys LV+dP/dt 
Ao CBF CVR (A-V)02dif MV02 
FIGURE 3. Summary of comparative 
changes in left ventricular (LV) function 
and coronary hemodynamics after ali- 
nidine administration at spontaneous at 
high matched pacing heart rates (HR). 
Although changes in indexes of LV 
function persisted at matched HR, there 
was no significant change in either 
coronary blood flow or. myocardial 
oxygen consumption (MVO& Ao = 
mean aortic pressure; (A-V)Os diff = 
arterial-coronary sinus difference in 
oxygen content; CBF = coronary blood 
flow; CVR = coronary vascular resis- 
tance; HR+LVsys = product of HR.LV 
peak systolic pressure; LV -I- dP/dt = 
peak rate of LV pressure; NS = not 
significant. 
m Spontaneous heart rate 
QJjllll High matched Pacing heart rate 
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the present study. That the negative inotropic property 
may nonetheless be important is confirmed by the 
finding of Simoons and HugenholtzlO that alinidine did 
lead to clinical heart failure in several patients with 
acute severe ischemic heart disease. 
Adm~~str~t~on of s&&&e $4~ 8.~ .?=+-.;-) .-? .’ ‘-i-J” uG UU”“““ilUl~ ;avePs 
of the metabolite cio&line after 3 hours that reach low 
peak levels in 8 to 9 hours.25t26 This would not affect the 
results obtained from this acute study, but could have 
a pharmacologic effect on sympathetic activity with 
chronic use. 
In stable patients, alinidine could offer an alternative 
to ,&blocking drug therapy in the presence of atrio- 
ventricular block, obstructive lung disease or potential 
hypoglycemia. Jn an initial report, when alinidine was 
compared to the P-blocker metoprolol in patients with 
chronic stable angina, both similarly reduced angina 
symptoms and increased maximal workload with no 
limiting side effects encountered with either drugJ7 
Alinidine, however, led to a smaller reduction in HR at 
rest, maximal exercise HR and maximal exercise rate- 
pressure product. The role of the metabolite clonidine 
will also have to be assessed, because this agent has also 
been reported to be beneficial in patients with angina 
pectoris.28 
Whether patients with LV dysfunction can tolerate 
alinidine better than P-blocking drugs is uncertain. 
Theoretically, in patients with severe heart failure re- 
quiring inotropic support with catecholamines, alinidine 
could prevent an undesired tachycardia while relatively 
preserving inotropic augmentation.2g In general, how- 
ever, any bradycardic and negative inotropic agent is 
contraindicated in patients critically dependent on 
sympathetic stimulation in whom cardiac output is 
maintained by an increased HR. 
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